Metal-Organic Frameworks Applied in Bone Disorders

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 5352

Special Issue Editors

Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
Interests: solid-solid reactions by mechanochemistry; cyclodextrin inclusion compounds; solubilization of active pharmaceutical ingredients (APIs); local therapeutic systems for osteosarcoma and osteoporosis; antioxidant flavonoids and their Ru(II) complexes; natural and metallo-organic compounds for cytotoxic and biocidal activities; innovative medicines for leishmaniasis based on inorganic complexes and cyclodextrins
Special Issues, Collections and Topics in MDPI journals
Department of Chemistry, CICECO−Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal
Interests: chemistry and preparation of metal-organic frameworks and coordination polymers in general; design of functional materials, which include photoluminescence, proton conductivity and catalysis; chemical crystallography
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Research in metal–organic frameworks (MOFs) has changed in the last two decades, from simple crystallographic architectures to very complex new materials, ultimately redesigning the way that chemists (and scientists in general) look into traditional coordination chemistry. This rapid change has been very much motivated by the symbiotic combination of organic and inorganic components, which has allowed for the embodiment of materials with new, interesting properties.

MOFs designed for medicinal and biomedical engineering applications are reported in growing numbers. From drug delivery to cancer therapy and theranostics, these biomaterials are slowly making their way to use in human health. The expanding knowledge of their biocompatibility and metabolic fate is strongly contributing to this transition to clinics.

This Special Issue will create a forum for the presentation of the most relevant progress on the aforementioned particular class of MOFs, that are dedicated to the treatment, management or diagnostic of bone disorders. The Special Issue will significantly benefit from the simultaneous contribution of original research articles, as well as of pertinent and critical review articles in this scientific field.

Dr. Susana Santos Braga
Dr. Filipe Alexandre Almeida Paz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Bio-MOFs
  • Bone metabolism
  • Drug delivery
  • Bone-compatible materials
  • Prosthetics
  • Osteoporosis
  • Osteosarcoma
  • Imaging techniques

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 5749 KiB  
Article
Calcium and Strontium Coordination Polymers as Controlled Delivery Systems of the Anti-Osteoporosis Drug Risedronate and the Augmenting Effect of Solubilizers
by Maria Vassaki, Christina Kotoula, Petri Turhanen, Duane Choquesillo-Lazarte and Konstantinos D. Demadis
Appl. Sci. 2021, 11(23), 11383; https://0-doi-org.brum.beds.ac.uk/10.3390/app112311383 - 01 Dec 2021
Cited by 11 | Viewed by 2029
Abstract
Bisphosphonates (BPs) constitute a class of drugs used for the treatment of calcium- and bone-related disorders, including osteoporosis, Paget’s disease, etc. The presence of the anionic phosphonate groups endows them with the ability to act as ligands to metal ions. As a result, [...] Read more.
Bisphosphonates (BPs) constitute a class of drugs used for the treatment of calcium- and bone-related disorders, including osteoporosis, Paget’s disease, etc. The presence of the anionic phosphonate groups endows them with the ability to act as ligands to metal ions. As a result, the synthesis of complexes or coordination polymers of various structural motifs can be accomplished. In this work, the 3rd generation BP drug risedronate (RIS) was combined with biologically acceptable alkaline earth metal ions (e.g., Ca2+ and Sr2+) in an effort to synthesize new materials. These metal–RIS compounds can operate as controlled delivery systems (CDSs) when exposed to appropriate experimental conditions, such as the low pH of the human stomach. CDS networks containing Ca2+ or Sr2+ and RIS were physicochemically and structurally characterized and were evaluated for their ability to release the free RIS drug during an acid-driven hydrolysis process. Due to the low solubility of RIS at low pH, cationic additives (linear polyethyleneimine and amine-terminated polyaminoamide dendrimer) were utilized as drug solubilizers. Based on the drug release results of this study, there was an attempt to correlate the drug release efficiency with the structural features of these CDSs. Full article
(This article belongs to the Special Issue Metal-Organic Frameworks Applied in Bone Disorders)
Show Figures

Graphical abstract

Review

Jump to: Research

12 pages, 2082 KiB  
Review
The Emerging Role of Cyclodextrin Metal–Organic Frameworks in Ostheotherapeutics
by Susana Santos Braga and Filipe A. Almeida Paz
Appl. Sci. 2022, 12(3), 1574; https://0-doi-org.brum.beds.ac.uk/10.3390/app12031574 - 01 Feb 2022
Cited by 3 | Viewed by 2502
Abstract
Metal–Organic Frameworks (MOFs) are a class of coordination compounds with high versatility of design and a high loading ability. These properties have made them increasingly attractive for drug delivery, with research focusing mostly on the preparation of biocompatible MOFs. A suitable strategy is [...] Read more.
Metal–Organic Frameworks (MOFs) are a class of coordination compounds with high versatility of design and a high loading ability. These properties have made them increasingly attractive for drug delivery, with research focusing mostly on the preparation of biocompatible MOFs. A suitable strategy is the use of cyclodextrins, cyclic oligosaccharides with excellent biosafety profiles. This review summarises the early steps taken in the application of cyclodextrin-coated and cyclodextrin-based MOFs in the treatment of bone-related diseases divided into three categories: cyclodextrin-coated MOFs, cyclodextrin-based MOFs and cross-linked derivatives of CD-MOFs. Applications in the delivery of bisphosphonates, osteoporotic regulating drugs and non-steroidal anti-inflammatory drugs, for osteoarthritis management, are highlighted. Lastly, the use of these materials in dentistry is exemplified with a recent report. Full article
(This article belongs to the Special Issue Metal-Organic Frameworks Applied in Bone Disorders)
Show Figures

Figure 1

Back to TopTop